Stock SYNACT SYNACT PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases SynAct Pharma AB

Equities

SYNACT

SE0008241491

Delayed Nasdaq Stockholm
Other stock markets
 10:23:09 22/05/2024 BST 		5-day change 1st Jan Change
6.955 SEK -3.34% Intraday chart for SynAct Pharma AB -3.40% -21.23%
04-23 Synact Pharma AB Announces Changes in Nomination Committee Ahead of the 2024 Annual General Meeting CI
03-20 Sweden's SynAct Pharma Names New CEO MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioStock: SynAct Pharma's CEO provides an update
AQ
Change in number of shares and votes in SynAct Pharma AB
AQ
Notice of annual general meeting in SynAct Pharma AB
AQ
Bulletin from the extraordinary general meeting of SynAct Pharma AB
AQ
SynAct Pharma : Changes in SynAct Pharma's Nomination Committee ahead of the 2024 Annual General Meeting
PU
Changes in SynAct Pharma’s Nomination Committee ahead of the 2024 Annual General Meeting
AQ
BioStock: Synact focuses on pushing forward rheumatoid arthritis project
AQ
Notice of extraordinary general meeting in SynAct Pharma AB
AQ
SynAct Pharma : has successfully completed the bookbuilding procedure - directed issues provide the company with a total of up to 49.2 MSEK.
PU
SynAct Pharma AB announces intention to carry out directed share issues in total of approximately 48 MSEK
AQ
SynAct Pharma publishes Annual Report 2023
AQ
SynAct Pharma AB (publ) ("SynAct") brings forward the publication of the annual report.
AQ
SynAct Pharma comments on ownership changes among senior executives
AQ
Synact's new CEO to BioStock: "I'm hitting the ground running"
AQ
SynAct Pharma appoints Jeppe Øvlesen CEO
AQ
Bulletin from the extraordinary general meeting of SynAct Pharma AB
AQ
SynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis
AQ
Marina Bozilenko resigns from Board of Directors of SynAct Pharma
AQ
SynAct Pharma AB (publ) (“SynAct”) today publishes the fourth quarter and annual results of 2023.
AQ
SynAct Pharma publishes Q3 2023 interim report
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SYNACT Stock
  4. News SynAct Pharma AB
  5. Press Releases